AFL Aflac
Elite, durable Japan franchise, but buyback-limited book growth and yen drag leave shares priced above fair value.
The story
Aflac runs a dominant, high-margin supplemental health and cancer insurance franchise in Japan and the US. Underwriting is consistently profitable and the balance sheet is conservatively reserved. Trailing ROE of 16.5% is inflated: rising JGB yields have pushed down AOCI, which shrinks the reported book. Revenue keeps slipping (about 3% a year over five years) because of yen weakness and a mature Japan block. Heavy buybacks of roughly $3B a year return most earnings rather than compounding book, and through-the-cycle returns should sit closer to the low-to-mid teens.
I moved ROE up 50bp from 13.5% to 14% because the higher returns have held for several quarters. I did not extrapolate the 16.5% trailing figure, because the AOCI-depressed denominator and realized gains flatter it. Book growth stays low because buybacks and dividends take out most of earnings and the yen translation drags on reported equity. Beta stays at the 0.9 industry anchor, and failure risk is minimal given the reserving discipline and capital buffers.
Value drivers
| Return on equity (normalized) | 14.0% |
| Book-value growth (Y1) | 3.0% |
| Terminal book growth | 2.5% |
| Beta | 0.90 |
| Failure probability | 1.0% |
| Cost of equity | 9.0% |
Valuation bridge
| PV of excess returns | 7.77B |
| PV of terminal excess | 5.05B |
| Equity value | 41.89B |
| ÷ shares → per share | $83.55 |
Projected excess returns on equity
| Yr | Book equity | ROE | Excess return | PV |
|---|---|---|---|---|
| 1 | 29.49B | 14.0% | 1.48B | 1.36B |
| 2 | 30.37B | 13.7% | 1.42B | 1.20B |
| 3 | 31.27B | 13.3% | 1.36B | 1.05B |
| 4 | 32.17B | 13.0% | 1.29B | 915.57M |
| 5 | 33.08B | 12.7% | 1.22B | 791.69M |
| 6 | 34.00B | 12.3% | 1.14B | 678.50M |
| 7 | 34.93B | 12.0% | 1.05B | 575.33M |
| 8 | 35.86B | 11.7% | 957.94M | 481.50M |
| 9 | 36.80B | 11.3% | 859.44M | 396.40M |
| 10 | 37.74B | 11.0% | 754.73M | 319.42M |
Key risks
- Further yen depreciation shrinks reported USD earnings and book
- Japan third-sector sales stagnate and the policyholder base ages, which erodes revenue
- Credit losses in the US corporate and private-credit investment portfolio, or JGB rate volatility hitting ESR and capital
Catalysts
- Higher Japanese reinvestment yields lift net investment income over time
- Product launches such as new cancer and medical riders reviving Japan sales momentum